Dihydroergotamine Nasal Spray [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2019-06-26 12:47 (570 d 06:25 ago) – Posting: # 20363
Views: 1,801

Hi all,


» » If it is required, …
»
» It is. If you would deviate from a guidance without a controlled correspondence you risk an RtR.

It would be an interesting lawsuit, if the company gets an RtR for lack of baseline correction and sues the FDA because the formal requirement is meaningless.
Perhaps a case where FDA could hide behind the fact that it is a draft and contains nonbinding recommendations blahblah?

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,303 posts in 4,441 threads, 1,487 registered users;
online 5 (0 registered, 5 guests [including 5 identified bots]).
Forum time: Saturday 18:12 CET (Europe/Vienna)

If you can’t solve a problem, then there is an easier problem
you can solve: find it.    George Pólya

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5